Moreover, AZD4547 did not demonstrate a significantly improved PFS compared to paclitaxel (1.8 months for AZD4547 vs. 3.5 months for paclitaxel) in patients with FGFR2-amplified or polysomic gastric cancer (GC) in the second-line setting in another phase II trial (NCT01457846)21. The gene discussed is FGFR2; the disease is gastric cancer.